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ABSTRACT
In cardiac surgery patients, intracoronary 
(IC) administration of levosimendan can 
provide optimal drug spread, enabling ef-
fective manifestation of favorable drug 
effects and avoiding potentially harm-
ful systemic hypotension. This could be 
beneficial in acute coronary syndromes 
(ACS) with decreased left ventricular ejec-
tion fraction (LVEF). We present ten cases 
of IC administration of levosimendan in 
ACS manifested as ST segment elevation 
myocardial infarction, non-ST segment el-
evation myocardial infarction or unstable 
angina pectoris. All patients underwent 
coronary artery bypass graft (CABG) sur-
gery, performed as an “off-pump” or “on-
pump”/“off-clamp” procedure (latter one 
with the use of cardiopulmonary bypass on 
the beating heart). Levosimendan was ad-
ministered as an IC bolus (125-250 μg) in 
each coronary artery graft (2-3 grafts). In-
travenous (IV) levosimendan infusion con-
tinued (0.1-0.2 μg•kg-1•min-1) after graft 
placements (24-48 h), with IV infusion of 
norepinephrine (0.1 mg•ml-1), if needed. 
Cardiac function was assessed using LVEF 
(%) (Teicholz), thermodilution cardiac in-
dex (CI) (ml•m-2), and systemic vascular 
resistance (SVR) (dynes•sec•cm-5). 
Nonparametric Wilcoxon signed-ranks 
test [presented as median (MED) with 
interquartile range (IQR)] indicated a sig-
nificant difference between preoperative 
vs. immediate postoperative CI, SVR, and 
LVEF in all cases [2.2 (1.9-2.5) vs. 3.1 (2.9-
3.4) ml•m-2, 1173.0 (1062.7-1278.2) vs. 
882.5 (763.5-993.0) dynes•sec•cm-5, 44.5 
(36.0-46.7) vs. 53.5 (45.7-59.2) %, respec-
tively] (P=0.005), i.e. IC administration of 
levosimendan was associated with prompt 
improvement of intraoperative hemody-
namics and cardiac contractility.  IC ad-
ministration of levosimendan may be a 
promising alternative method for improv-
ing decreased cardiac function in acute 
cardiac ischemia, besides necessary surgi-
cal revascularization.
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INTRODUCTION
Patients with acute coronary syndrome 
(ACS), undergoing surgical myocardial re-
vascularization, are susceptible to contrac-
tile myocardial dysfunction with hemo-
dynamic compromise, often necessitating 
inotropic and/or mechanical circulatory 
support. (1,2) Consequently, perioperative 
preservation of heart function and the use 
of optimal inotropic agents are becoming 
strongly emphasized. (2,3) A calcium-sen-
sitizing drug, levosimendan, has emerged 
as a novel inotropic agent with vasodilator 
properties and potent cardioprotective ef-
fects, all especially beneficial in coronary 
artery disease (CAD). (2,4) The periopera-
tive use of levosimendan in cardiac surgery 
patients has been associated with a reduc-
tion in myocardial injury, improvement 
of hemodynamics and clinical outcomes, 
and reduction in additional inotropic and/
or mechanical circulatory support. (1,4) 
In the majority of studies, levosimendan 
is usually administered as a continuous 
intravenous (IV) infusion over 24 h. (4) 
However, IV use of levosimendan could be 
limited by extensive systemic vasodilata-
tion and hypotension, particularly in CAD. 
(5) Intracoronary (IC) administration of 
levosimendan was proposed as a possible 
strategy for effective regional myocardial 
drug distribution, facilitating favorable 
and avoiding potentially harmful drug ef-
fects. (6-9)  
We present 10 cases of IC administration 
of levosimendan in ACS with decreased 
left ventricular ejection fraction (LVEF), 
manifested as ST segment elevation myo-
cardial infarction (STEMI), non-ST seg-
ment elevation myocardial infarction 
(NSTEMI) or unstable angina pectoris 
(AP), requiring coronary artery bypass 
graft (CABG) surgery. 
MATERIALS AND METHODS
The study was approved by the local Eth-
ics Committee of the University Hospital 
Split.
Technical aspects of IC levosimendan 
administration
CABG surgery was performed as an “off-
pump” or “on-pump”/“off-clamp” proce-
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dure, the latter with the use of cardiopul-
monary bypass (CPB) on the beating heart. 
Levosimendan was administered as an IC 
bolus injected in each coronary artery 
graft. Levosimendan was first diluted (12.5 
mg in 50 ml of 5% glucose solution, 250 
μg•ml-1). Two ml of this drug solution was 
mixed with the patients heparinized blood 
in a 20 ml syringe (25 μg•ml-1). Prepared 
content from the syringe was forwarded 
to the surgery team in sterile conditions. 
A surgeon administered 5-10 ml (125-
250 μg) in each coronary artery graft (2-3 
grafts). After the completion of CABG 
surgery, IV infusion of levosimendan con-
tinued (0.1-0.2 μg•kg-1•min-1) to prolong 
drug delivery (24-48 h), with IV infusion 
of norepinephrine (0.1 mg•ml-1), if need-
ed.
Patients
Our first case (45-year-old female in acute 
STEMI), was done unintentionally in an 
urgent manner, due to acute onset of my-
ocardial stunning during weaning from 
CPB. Surgical revascularization started as 
Off-pump coronary artery bypass (OP-
CAB),, but after the first bypass was com-
pleted, the patient experienced sudden 
hemodynamic instability. An intra-aortic 
balloon pump (IABP) was positioned 
without expected improvement. Urgent 
CPB was initiated in order to place two 
additional grafts. During the very chal-
lenging process of weaning (hemodynamic 
compromise, several weaning attempts), 
we decided to administer an IC bolus of 
levosimendan in each coronary artery 
graft (in consultancy with colleagues from 
abroad). Soon after, the patient was suc-
cessfully weaned from CPB with evident 
intraoperative improvement of hemody-
namics and overall cardiac function. We 
continued with IC levosimendan adminis-
tration in several subsequent acute STEMI 
cases with troponin I over 50 ng•ml-1 (5 
cases). Additionally, as we continued, we 
found this method to be beneficial in more 
complicated cases of advanced chronic 
CAD manifested in acute form, as unsta-
ble AP (4 cases) or acute NSTEMI (1 case), 
with moderately elevated troponin I.
Perioperative evaluation of cardiac 
function and outcomes
Cardiac function was obtained with perio-
perative heart ultrasound estimation of 
LVEF (%) (Teicholz), thermodilution car-
diac index (CI) (ml•m-2), and systemic vas-
cular resistance (SVR) (dynes•sec•cm-5). 
Troponin I (ng•ml-1) was measured pre-
operatively and checked regularly. Time to 
extubation, intensive care unit (ICU) and 
hospital discharge were expressed in post-
operative days (POD). POD 1 represented 
the first day following the day of surgery.
Statistical analysis
The results were analyzed using statistical 
program SPSS 14.0 with nonparametric 
Wilcoxon signed-ranks test for compari-
sons of preoperative vs. immediate post-
operative values (or ICU discharge values 
for troponin I) of CI, SVR, LVEF, and 
troponin I variables in all patients. Data 
were presented as median (MED) with in-
terquartile range (IQR). Statistical signifi-
cance was set at P<0.05.
RESULTS
General characteristics, clinical findings 
and outcomes in each of ten patients are 
presented in table 1. Comparing preop-
erative vs. immediate postoperative CI, 
SVR, and LVEF in all patients (table 2), IC 
administration of levosimendan exerted 
significant improvement of intraoperative 
hemodynamics and cardiac contractility 
(P=0.005). Preoperative vs. ICU discharge 
troponin I decreased in all cases (P=0.005) 
(table 2).  
DISCUSSION
In this short report, IC administration of 
levosimendan was associated with evident 
improvement in intraoperative hemody-
namics and overall cardiac function. 
Jamali et al. have previously found that IC 
levosimendan administration enhances 
contractile function of stunned myocar-
dium. (10) Several subsequent animal 
studies pointed to its cardioprotective and 
antiapoptotic effects. (6,7) In humans, IC 
administration of levosimendan improved 
systolic and diastolic cardiac function, in 
ischemic and non-ischemic acute heart 
failure, without significant systemic hypo-
tension. (8,9) Our main reason for IC ad-
ministration of levosimendan was globally 
hypokinetic myocardium with reduced 
overall cardiac function evident in every 
patient. Patients who underwent an “on 
pump”/”off-clamp” procedure were suc-
cessfully weaned from CPB. In “off pump” 
cases, an IC bolus was first administered 
after the placement of the first graft, ena-
bling hemodynamic stability and proce-
dure continuation. In previous studies, IC 
levosimendan was used in variable doses, 
as an IC bolus or short continuous IC infu-
sion. (7-9) An ongoing clinical trial chose 
a 12 μg•kg-1 dose of IC levosimendan 
infusion at the induction of cardioplegia 
(after opening of the aortic cross-clamp 
in aortic valve/CABG surgery). (4) Our 
125-250 μg IC bolus administered in each 
coronary artery graft (2-3 grafts) during 
surgical revascularization, corresponded 
approximately to the 6-12 μg•kg-1 dose 
of IC levosimendan administered to each 
patient. Many questions arise regarding 
the right timing for IC levosimendan ad-
ministration, optimal dose, category of pa-
tients that could benefit, and the relevant 
outcome measures. Further randomized 
control studies and/or more case series are 
needed to provide the correct answers. 
In conclusion, as we used an IV infusion 
of levosimendan (following graft place-
ments) and surgical revascularization, it is 
not possible to define the exact contribu-
tion of IC levosimendan to the final clini-
cal outcome. However, we believe that IC 
administration of levosimendan may be a 
useful alternative method for improving 
decreased cardiac function in acute onset 
cardiac ischemia, in addition to necessary 
surgical revascularization. 
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Table 1. General characteristics, clinical findings and outcomes in patients with ACS administered IC levosimendan during CABG surgery.
case gender/ age
BMI







preop. / ICU 
discharge
outcomes
1 F / 45
23.0





3 boluses + 0.1-0.2 μg/
kg/min (48 h)
CI 1.9 / 3.0
SVR 1223 / 1000
LVEF 44% / 53%
> 50 / 7.044 extubation - POD 3
ICU discharge - POD 5
hospital discharge - 
POD 18
2 M / 68
27.4
STEMI CABG x 3
IABP
previous 1 MI, 
AH
3 boluses + 0.1-0.2 μg/
kg/min (36 h)
CI 2.6 / 3.3
SVR 1071 / 919
LVEF 45% / 57%
> 50 / 19.442 extubation - POD 1
ICU discharge - POD 3
hospital discharge - 
POD 9
3 F / 44
34.2
STEMI CABG x 3
IABP




3 boluses + 0.15-0.2 
μg/kg/min (24 h)
CI 2.7 / 3.8
SVR 1237 / 810
LVEF 50% / 60%
> 50 / 15.134 extubation - POD 3
ICU discharge - POD 6
hospital discharge - 
POD 12
4 F / 70
29.3
STEMI CABG x 3 AH 3 boluses + 0.1-0.15 
μg/kg/min (24 h)
CI 2.4 / 2.9
SVR 1123 / 972
LVEF 46% / 54%
> 50 / 22.864 extubation - POD 1
ICU discharge - POD 2
hospital discharge - 
POD 7
5 F / 57
24.9
STEMI CABG x 3 AH, DM, IABP 
on POD 1
3 boluses + 0.1-0.15 
μg/kg/min (48 h)
CI 2.3 / 2.9
SVR 1738 / 1264
LVEF 36% / 48%
> 50 / 20.416 extubation - POD 2
ICU discharge - POD 5
hospital discharge - 
POD 11
6 M / 69
29.4




2 boluses + 0.1-0.15 
μg/kg/min for 48 h
CI 2.7 / 3.2
SVR 970 / 687
LVEF 36% / 45%
0.878 / 0.212 extubation - POD 1
ICU discharge - POD 5
hospital discharge - 
POD 11
7 M / 63
25.1






3 boluses + 0.1-0.15 
μg/kg/min (24 h)
CI 1.9 / 3.5
SVR 1299 / 679
LVEF 22% / 45%
1.180 / 0.793 extubation - POD 1
ICU discharge - POD 2
hospital discharge - 
POD 7
8 M / 70
25.5
unstable AP OPCAB x 3 AF 3 boluses + 0.1-0.15 
μg/kg/min (36 h)
CI 2.2 / 3.1
SVR 1043 / 748
LVEF 27% / 39%
1.403 / 0.644 extubation - POD 1
ICU discharge - POD 2
hospital discharge - 
POD 9
9 M / 80
25.4
unstable AP OPCAB x 2 AH, DM, COPB
respiratory 
insufficiency
2 boluses + 0.1-0.2 μg/
kg/min (24 h)
CI 2.0 / 2.4
SVR 1060 / 846
LVEF 55% / 63%
3.081 / 0.626 extubation - POD 1
ICU discharge - POD 8
hospital discharge - 
POD 20
10 F / 66
25.2
unstable AP CABG x 2 AH, hypothy-
roidism
2 boluses + 0.1-0.2 μg/
kg/min (24 h)
CI 1.6 / 3.4
SVR 1292 / 1071
LVEF 47% / 60%
1.691 / 0.426 extubation - POD 1
ICU discharge - POD 4
hospital discharge - 
POD 9
ACC/ACE/ACI , common/external/internal carotid artery; ACS, acute coronary syndromes; AF, atrial fibrillation; AH, arterial hyper-
tension; AP, angina pectoris; BMI, body mass index; CABG, coronary artery bypass grafting (“on-pump” type of surgery); CI, cardiac 
index (ml•m-2); COPB, chronic obstructive pulmonary disease; CRRT, continuous renal replacement therapy; DM, diabetes mellitus; F, 
female; HD, hemodialysis; IABP, intra-aortic balloon pump; IC, intracoronary; ICU, intensive care unit; LVEF, left ventricular ejection 
fraction; M, male; MI, myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; OPCAB, “off-pump” coronary 
artery bypass (type of surgery); POD, postoperative day; STEMI, ST segment elevation myocardial infarction; SVR, systemic vascular 
resistance (dynes•sec•cm-5); TEA, thrombendarterectomy.
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Table 2. Preoperative vs. immediate postoperative values (or ICU discharge values for troponin I) of CI, SVR, LVEF, and troponin I vari-
ables in all patients (i.e. before and after IC administration of levosimendan).
variables preoperative MED (IQR) postoperative MED (IQR) P*
CI (ml•m-2) 2.2 (1.9-2.5) 3.1 (2.9-3.4) 0.005
SVR (dynes•sec•cm-5) 1173.0 (1062.7-1278.2) 882.5 (763.5-993.0) 0.005
LVEF (%) 44.5 (36.0-46.7) 53.5 (45.7-59.2) 0.005
troponin I (ng•ml-1) 26.54 (1.48-50) 3.92 (0.63-18.37) 0.005
CI, cardiac index; IQR, interquartile range; LVEF, left ventricular ejection fraction; MED, median; SVR, systemic vascular resistance. 
* P – value derived from Wilcoxon signed-ranks test; values presented as MED (IQR).
